Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E.
Other stock markets
 15:59:59 2024-06-27 EDT 		5-day change 1st Jan Change
2.74 CAD -3.52% Intraday chart for NervGen Pharma Corp. +20.18% +1.48%
06-26 Nervgen Pharma Initiated at Market Perform, $3 Price Target at Raymond James MT
06-25 NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage MT

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NervGen Pharma Corp. Approves Board and Audit Committee Elections
CI
Nervgen Pharma Corp. Announces That Bill Radvak, Nervgen's Current Chairman and Co-Founder Will Not Stand for Re-Election and Will Transition to A Continuing Role as an Advisor to the Board
CI
Nervgen Pharma Appoints John Ruffolo to Board of Directors
CI
Nervgen Pharma Corp. Appoints Michael Kelly as CEO
CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
MT
NervGen Pharma Corp. Announces Executive Changes
CI
NervGen Pharma Corp. Announces Executive Changes
CI
NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors
CI
NervGen Pharma Corp. Announces Executive Changes
CI
NervGen Pharma Corp. Announces Spinal Cord Injury Clinical Advisory Board
CI
NervGen Pharma Corp. Appoints Krista Mckerracher and Glenn Ives to Its Board of Directors
CI
NervGen Pharma Corp. Establishes Multiple Sclerosis Clinical Advisory Board
CI
NervGen Pharma Corp. Expands Alzheimer's Disease, Scientific Advisory Board
CI
NervGen Pharma Corp. Announces the Appointment of Daniel Mikol as Chief Medical Officer, Effective May 5, 2021
CI
NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board
CI
NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors
CI
NervGen Pharma Corp. Announces Resignation of Lloyd Mackenzie as Chief Operating Officer, Effective October 2, 2020
CI
NervGen Pharma Corp. Announces Management Changes
CI
NervGen Pharma Corp. Announces Management Changes
CI
NervGen Pharma Corp. Announces Appointment of Amy Franke as Vice President, Clinical Operations
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. News NervGen Pharma Corp.
  5. Insiders